Prelude Therapeutics boosts IPO proceeds target to up to $158M
September 23, 2020 at 10:57 AM EDT
The company is poised to become the fifth Philadelphia-area life sciences companies to go public this year through an IPO.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|